Partners Capital Investment Group LLP Sells 82,205 Shares of Bristol-Myers Squibb (NYSE:BMY)

Partners Capital Investment Group LLP cut its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 48.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,770 shares of the biopharmaceutical company's stock after selling 82,205 shares during the period. Partners Capital Investment Group LLP's holdings in Bristol-Myers Squibb were worth $5,021,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BMY. AMF Tjanstepension AB lifted its holdings in shares of Bristol-Myers Squibb by 6.9% during the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company's stock worth $31,618,000 after buying an additional 39,419 shares in the last quarter. Swedbank AB increased its holdings in shares of Bristol-Myers Squibb by 0.9% during the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock worth $162,440,000 after purchasing an additional 28,427 shares during the period. KMG Fiduciary Partners LLC increased its holdings in shares of Bristol-Myers Squibb by 2.0% during the third quarter. KMG Fiduciary Partners LLC now owns 31,066 shares of the biopharmaceutical company's stock worth $1,607,000 after purchasing an additional 618 shares during the period. Moss Adams Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter worth approximately $210,000. Finally, Blue Trust Inc. increased its holdings in shares of Bristol-Myers Squibb by 50.0% during the third quarter. Blue Trust Inc. now owns 25,501 shares of the biopharmaceutical company's stock worth $1,319,000 after purchasing an additional 8,498 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling

In other news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.09% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BMY. Leerink Partners upgraded shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Bank of America reiterated a "neutral" rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald increased their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Finally, Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $57.86.

Bristol-Myers Squibb Trading Up 1.5 %

Shares of NYSE:BMY traded up $0.82 during mid-day trading on Thursday, reaching $55.80. 8,949,679 shares of the company's stock were exchanged, compared to its average volume of 10,879,409. The firm has a market capitalization of $113.23 billion, a price-to-earnings ratio of -12.62, a PEG ratio of 2.02 and a beta of 0.45. The business's fifty day moving average price is $57.00 and its 200-day moving average price is $54.23. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's payout ratio is -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.